U.S. markets open in 6 hours 7 minutes

LeMaitre Vascular, Inc. (LMAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
62.30-0.59 (-0.94%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close62.89
Open63.00
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range60.75 - 63.63
52 Week Range23.95 - 63.64
Volume175,580
Avg. Volume116,920
Market Cap1.284B
Beta (5Y Monthly)1.34
PE Ratio (TTM)53.71
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.44 (0.71%)
Ex-Dividend DateMay 18, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference
    GlobeNewswire

    LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference

    BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on Thursday, June 10, 2021, at 5:30 PM ET. LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and im

  • LeMaitre Regains Five CE Marks
    GlobeNewswire

    LeMaitre Regains Five CE Marks

    BURLINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it received CE marks under the European Medical Devices Directive (93/42/EC as amended by 2007/47/EC) for the following five products. Marks for the five products had previously lapsed due to a change in notified bodies. ProductNotified BodyExpiration DateXenoSure Biologic PatchesTUV SUDMay 26, 2024AlboGraft Polyester Vascular GraftsTUV SUDMay 26, 2024Pruitt Carotid ShuntsSGSMay 24, 2024Flexcel Carotid ShuntsSGSMay 24, 2024AnastoClip Closure SystemsSGSMay 24, 2024 The indications for use under the new CE mark for XenoSure no longer include neuro or cardiac applications, indications for which the product was approved under its prior CE mark. Additionally, only XenoSure made from bovine pericardium sourced from certain of our suppliers is permitted to be sold under the new CE mark. Andrew Hodgkinson, SVP of Clinical, Regulatory & Quality Affairs, said, “While our customers have largely enjoyed uninterrupted supply of most of these devices due to inventory stockpiles and local derogations, we are pleased to have received these five CE marks before the transition to the new Medical Device Regulation in the EU on May 26, 2021. We emerge from this transition having lost CE marks on several smaller product lines totaling just 3% of our 2019 EMEA sales.” About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company. For more information about the Company, please visit http://www.lemaitre.com. CONTACT: Contact: Sandra Millar LeMaitre Vascular, Inc. +1-781-425-1686 smillar@lemaitre.com

  • LeMaitre to Present at the Jefferies Virtual Healthcare Conference
    GlobeNewswire

    LeMaitre to Present at the Jefferies Virtual Healthcare Conference

    BURLINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 PM EDT. LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com. Contact:Sandra MillarLeMaitre Vascular, Inc. +1-781-425-1686smillar@lemaitre.com